Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma

Srinivasan Senthamizhchelvan, Robert F. Hobbs, Hong Song, Eric C. Frey, Zhe Zhang, Elwood Armour, Richard L. Wahl, David M. Loeb, George Sgouros

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

153Sm-ethylenediamine tetramethylene phosphonic acid ( 153Sm-EDTMP) therapy for osteosarcoma is being investigated. In this study, we analyzed the influence of 153Sm-EDTMP administered activity (AA), osteosarcoma tumor density, mass, and the shape of the tumor on absorbed dose (AD). We also studied the biologic implication of the nonuniform tumor AD distribution using radiobiologic modeling and examined the relationship between tumor AD and response. Methods: Nineteen tumors in 6 patients with recurrent, refractory osteosarcoma enrolled in a phase I or II clinical trial of 153Sm-EDTMP were analyzed using the 3-dimensional radiobiologic dosimetry (3D-RD) software package. Patients received a low dose of 153Sm-EDTMP (37.0-51.8 MBq/kg), followed on hematologic recovery by a second, high dose (222 MBq/kg). Treatment response was evaluated using either CT or MRI after each therapy. SPECT/CT of the tumor regions were obtained at 4 and 48 h or 72 h after 153Sm-EDTMP therapy for 3D-RD analysis. Mean tumor AD was also calculated using the OLINDA/EXM unit-density sphere model and was compared with the 3D-RD estimates. Results: On average, a 5-fold increase in the AA led to a 4-fold increase in the mean tumor AD over the high- versus low-dose-treated patients. The range of mean tumor AD and equivalent uniform dose (EUD) for low-dose therapy were 1.48-14.6 and 0.98-3.90 Gy, respectively. Corresponding values for high-dose therapy were 2.93-59.3 and 1.89-12.3 Gy, respectively. Mean tumor AD estimates obtained from OLINDA/EXM were within 5% of the mean AD values obtained using 3D-RD. On an individual tumor basis, both mean AD and EUD were positively related to percentage tumor volume reduction (P = 0.031 and 0.023, respectively). Conclusion: The variations in tumor density, mass, and shape seen in these tumors did not affect the mean tumor AD estimation significantly. The tumor EUD was approximately 2- and 3-fold lower than the mean AD for low- and high-dose therapy, respectively. A dose-response relationship was observed for transient tumor volume shrinkage.

Original languageEnglish (US)
Pages (from-to)215-224
Number of pages10
JournalJournal of Nuclear Medicine
Volume53
Issue number2
DOIs
StatePublished - Feb 1 2012
Externally publishedYes

Fingerprint

ethylenediamine
Osteosarcoma
Neoplasms
Therapeutics
phosphonic acid
Tumor Burden

Keywords

  • Sm
  • Osteosarcoma
  • Radiobiologic dosimetry
  • Radiopharmaceutical therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Senthamizhchelvan, S., Hobbs, R. F., Song, H., Frey, E. C., Zhang, Z., Armour, E., ... Sgouros, G. (2012). Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. Journal of Nuclear Medicine, 53(2), 215-224. https://doi.org/10.2967/jnumed.111.096677

Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. / Senthamizhchelvan, Srinivasan; Hobbs, Robert F.; Song, Hong; Frey, Eric C.; Zhang, Zhe; Armour, Elwood; Wahl, Richard L.; Loeb, David M.; Sgouros, George.

In: Journal of Nuclear Medicine, Vol. 53, No. 2, 01.02.2012, p. 215-224.

Research output: Contribution to journalArticle

Senthamizhchelvan, S, Hobbs, RF, Song, H, Frey, EC, Zhang, Z, Armour, E, Wahl, RL, Loeb, DM & Sgouros, G 2012, 'Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma', Journal of Nuclear Medicine, vol. 53, no. 2, pp. 215-224. https://doi.org/10.2967/jnumed.111.096677
Senthamizhchelvan, Srinivasan ; Hobbs, Robert F. ; Song, Hong ; Frey, Eric C. ; Zhang, Zhe ; Armour, Elwood ; Wahl, Richard L. ; Loeb, David M. ; Sgouros, George. / Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma. In: Journal of Nuclear Medicine. 2012 ; Vol. 53, No. 2. pp. 215-224.
@article{1ae12760ec464cb680452e394332bc3b,
title = "Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma",
abstract = "153Sm-ethylenediamine tetramethylene phosphonic acid ( 153Sm-EDTMP) therapy for osteosarcoma is being investigated. In this study, we analyzed the influence of 153Sm-EDTMP administered activity (AA), osteosarcoma tumor density, mass, and the shape of the tumor on absorbed dose (AD). We also studied the biologic implication of the nonuniform tumor AD distribution using radiobiologic modeling and examined the relationship between tumor AD and response. Methods: Nineteen tumors in 6 patients with recurrent, refractory osteosarcoma enrolled in a phase I or II clinical trial of 153Sm-EDTMP were analyzed using the 3-dimensional radiobiologic dosimetry (3D-RD) software package. Patients received a low dose of 153Sm-EDTMP (37.0-51.8 MBq/kg), followed on hematologic recovery by a second, high dose (222 MBq/kg). Treatment response was evaluated using either CT or MRI after each therapy. SPECT/CT of the tumor regions were obtained at 4 and 48 h or 72 h after 153Sm-EDTMP therapy for 3D-RD analysis. Mean tumor AD was also calculated using the OLINDA/EXM unit-density sphere model and was compared with the 3D-RD estimates. Results: On average, a 5-fold increase in the AA led to a 4-fold increase in the mean tumor AD over the high- versus low-dose-treated patients. The range of mean tumor AD and equivalent uniform dose (EUD) for low-dose therapy were 1.48-14.6 and 0.98-3.90 Gy, respectively. Corresponding values for high-dose therapy were 2.93-59.3 and 1.89-12.3 Gy, respectively. Mean tumor AD estimates obtained from OLINDA/EXM were within 5{\%} of the mean AD values obtained using 3D-RD. On an individual tumor basis, both mean AD and EUD were positively related to percentage tumor volume reduction (P = 0.031 and 0.023, respectively). Conclusion: The variations in tumor density, mass, and shape seen in these tumors did not affect the mean tumor AD estimation significantly. The tumor EUD was approximately 2- and 3-fold lower than the mean AD for low- and high-dose therapy, respectively. A dose-response relationship was observed for transient tumor volume shrinkage.",
keywords = "Sm, Osteosarcoma, Radiobiologic dosimetry, Radiopharmaceutical therapy",
author = "Srinivasan Senthamizhchelvan and Hobbs, {Robert F.} and Hong Song and Frey, {Eric C.} and Zhe Zhang and Elwood Armour and Wahl, {Richard L.} and Loeb, {David M.} and George Sgouros",
year = "2012",
month = "2",
day = "1",
doi = "10.2967/jnumed.111.096677",
language = "English (US)",
volume = "53",
pages = "215--224",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "2",

}

TY - JOUR

T1 - Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma

AU - Senthamizhchelvan, Srinivasan

AU - Hobbs, Robert F.

AU - Song, Hong

AU - Frey, Eric C.

AU - Zhang, Zhe

AU - Armour, Elwood

AU - Wahl, Richard L.

AU - Loeb, David M.

AU - Sgouros, George

PY - 2012/2/1

Y1 - 2012/2/1

N2 - 153Sm-ethylenediamine tetramethylene phosphonic acid ( 153Sm-EDTMP) therapy for osteosarcoma is being investigated. In this study, we analyzed the influence of 153Sm-EDTMP administered activity (AA), osteosarcoma tumor density, mass, and the shape of the tumor on absorbed dose (AD). We also studied the biologic implication of the nonuniform tumor AD distribution using radiobiologic modeling and examined the relationship between tumor AD and response. Methods: Nineteen tumors in 6 patients with recurrent, refractory osteosarcoma enrolled in a phase I or II clinical trial of 153Sm-EDTMP were analyzed using the 3-dimensional radiobiologic dosimetry (3D-RD) software package. Patients received a low dose of 153Sm-EDTMP (37.0-51.8 MBq/kg), followed on hematologic recovery by a second, high dose (222 MBq/kg). Treatment response was evaluated using either CT or MRI after each therapy. SPECT/CT of the tumor regions were obtained at 4 and 48 h or 72 h after 153Sm-EDTMP therapy for 3D-RD analysis. Mean tumor AD was also calculated using the OLINDA/EXM unit-density sphere model and was compared with the 3D-RD estimates. Results: On average, a 5-fold increase in the AA led to a 4-fold increase in the mean tumor AD over the high- versus low-dose-treated patients. The range of mean tumor AD and equivalent uniform dose (EUD) for low-dose therapy were 1.48-14.6 and 0.98-3.90 Gy, respectively. Corresponding values for high-dose therapy were 2.93-59.3 and 1.89-12.3 Gy, respectively. Mean tumor AD estimates obtained from OLINDA/EXM were within 5% of the mean AD values obtained using 3D-RD. On an individual tumor basis, both mean AD and EUD were positively related to percentage tumor volume reduction (P = 0.031 and 0.023, respectively). Conclusion: The variations in tumor density, mass, and shape seen in these tumors did not affect the mean tumor AD estimation significantly. The tumor EUD was approximately 2- and 3-fold lower than the mean AD for low- and high-dose therapy, respectively. A dose-response relationship was observed for transient tumor volume shrinkage.

AB - 153Sm-ethylenediamine tetramethylene phosphonic acid ( 153Sm-EDTMP) therapy for osteosarcoma is being investigated. In this study, we analyzed the influence of 153Sm-EDTMP administered activity (AA), osteosarcoma tumor density, mass, and the shape of the tumor on absorbed dose (AD). We also studied the biologic implication of the nonuniform tumor AD distribution using radiobiologic modeling and examined the relationship between tumor AD and response. Methods: Nineteen tumors in 6 patients with recurrent, refractory osteosarcoma enrolled in a phase I or II clinical trial of 153Sm-EDTMP were analyzed using the 3-dimensional radiobiologic dosimetry (3D-RD) software package. Patients received a low dose of 153Sm-EDTMP (37.0-51.8 MBq/kg), followed on hematologic recovery by a second, high dose (222 MBq/kg). Treatment response was evaluated using either CT or MRI after each therapy. SPECT/CT of the tumor regions were obtained at 4 and 48 h or 72 h after 153Sm-EDTMP therapy for 3D-RD analysis. Mean tumor AD was also calculated using the OLINDA/EXM unit-density sphere model and was compared with the 3D-RD estimates. Results: On average, a 5-fold increase in the AA led to a 4-fold increase in the mean tumor AD over the high- versus low-dose-treated patients. The range of mean tumor AD and equivalent uniform dose (EUD) for low-dose therapy were 1.48-14.6 and 0.98-3.90 Gy, respectively. Corresponding values for high-dose therapy were 2.93-59.3 and 1.89-12.3 Gy, respectively. Mean tumor AD estimates obtained from OLINDA/EXM were within 5% of the mean AD values obtained using 3D-RD. On an individual tumor basis, both mean AD and EUD were positively related to percentage tumor volume reduction (P = 0.031 and 0.023, respectively). Conclusion: The variations in tumor density, mass, and shape seen in these tumors did not affect the mean tumor AD estimation significantly. The tumor EUD was approximately 2- and 3-fold lower than the mean AD for low- and high-dose therapy, respectively. A dose-response relationship was observed for transient tumor volume shrinkage.

KW - Sm

KW - Osteosarcoma

KW - Radiobiologic dosimetry

KW - Radiopharmaceutical therapy

UR - http://www.scopus.com/inward/record.url?scp=84863079318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863079318&partnerID=8YFLogxK

U2 - 10.2967/jnumed.111.096677

DO - 10.2967/jnumed.111.096677

M3 - Article

VL - 53

SP - 215

EP - 224

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 2

ER -